Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center
Advertisement
Articles by Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center
Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.
HCC: Applying Recent Data Into Practice
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Emerging Therapies Under Investigation
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Combination Regimens for HCC Treatment
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Emerging Biomarkers in Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Liver Function and Treatment Decisions
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Safety Profiles of Novel Therapies for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Sequencing of Novel Therapies in HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Regorafenib or Cabozantinib for Second-Line HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Selecting Second-Line Therapy for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Second-Line Treatment for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Novel Combinations to Treat HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Immunotherapy in Liver Cancer
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Treating Patients With Atezolizumab/Bevacizumab
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
IO and VEGF Inhibition in Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Locoregional and Systemic Therapy for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Hepatocellular Carcinoma: Diagnostic Work-Up
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Surveillance for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Incidence of Liver Cancer in the US
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Advertisement
Latest Updated Articles
Dr. El-Khoueiry on the Frontline Treatment Landscape in HCCPublished: August 17th 2020 | Updated:
Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer CarePublished: March 17th 2023 | Updated:
Emerging Biomarkers in Hepatocellular CarcinomaPublished: July 13th 2020 | Updated:
Regorafenib or Cabozantinib for Second-Line HCCPublished: July 13th 2020 | Updated:
HCC: Emerging Therapies Under InvestigationPublished: July 13th 2020 | Updated:
Hepatocellular Carcinoma: Diagnostic Work-UpPublished: July 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5